ISLE
NASDAQIsleworth Healthcare Acquisition Corporation
Latest news
25 items- SECSEC Form 15-12G filed by Isleworth Healthcare Acquisition Corporation15-12G - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form 25-NSE filed by Isleworth Healthcare Acquisition Corporation25-NSE - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
- SECIsleworth Healthcare Acquisition Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- PRIsleworth Healthcare Acquisition Corp. Announces Cancellation of Special Meeting of Shareholders, Redemption of Public Shares and Subsequent DissolutionST. PETERSBURG, Fla., Aug. 25, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corp. (the "Company") (NASDAQ:ISLE, ISLEW))) today announced that it has cancelled its special meeting of shareholders that was previously scheduled for August 26, 2022, and that it will redeem all of its outstanding ordinary shares that were included in the units issued in its initial public offering (the "public shares"), effective as of the close of business on August 29, 2022, as the Company will not consummate an initial business combination on or prior to September 1, 2022. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combinati
- SECSEC Form 10-Q filed by Isleworth Healthcare Acquisition Corporation10-Q - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form DEF 14A filed by Isleworth Healthcare Acquisition CorporationDEF 14A - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form PRE 14A filed by Isleworth Healthcare Acquisition CorporationPRE 14A - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- PRISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENTST. PETERSBURG, Fla., June 30, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corporation (NASDAQ:ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has entered into an agreement with Cytovia Holdings, Inc. ("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the "Termination Agreement") to terminate its previously announced Merger Agreement with Cytovia, which was executed in April 2022. The Termination Agreement is effective immediately, and contains mutual releases and covenants not to sue. A copy of the Termination Agreement is filed as an exhibit to
- NEWSIsleworth Healthcare Acquistion, Cytovia Entered Into Termination Agreement Which Terminated Merger Deal, Effective Immediately-Reuters
- SECIsleworth Healthcare Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form 425 filed by Isleworth Healthcare Acquisition Corporation425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
- SECIsleworth Healthcare Acquisition Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form 425 filed by Isleworth Healthcare Acquisition Corporation425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
- SECSEC Form 425 filed by Isleworth Healthcare Acquisition Corporation425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
- SECIsleworth Healthcare Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- PRCytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 CongressData supports further development of CYT-338 in relapsed/refractory multiple myeloma AVENTURA, Fla. and NATICK, Mass., June 10, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites. For details on in-person poster presentations, please see the
- SECSEC Form 425 filed by Isleworth Healthcare Acquisition Corporation425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
- SECIsleworth Healthcare Acquisition Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form 425 filed by Isleworth Healthcare Acquisition Corporation425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
- SECIsleworth Healthcare Acquisition Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form 10-Q filed by Isleworth Healthcare Acquisition Corporation10-Q - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form 425 filed by Isleworth Healthcare Acquisition Corporation425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
- PRCytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 CongressAVENTURA, Fla. and NATICK, Mass., May 18, 2022 /PRNewswire/ -- Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association's (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022 at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online. The abstract was released on May 12, 2022. The e-poster present
- SECSEC Form NT 10-Q filed by Isleworth Healthcare Acquisition CorporationNT 10-Q - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)
- SECSEC Form 425 filed by Isleworth Healthcare Acquisition Corporation425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)
ISLE FAQ
6 questionsWhat does Isleworth Healthcare Acquisition Corporation do?
Isleworth Healthcare Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in St. Petersburg, Florida.Where does ISLE stock trade?
Isleworth Healthcare Acquisition Corporation (ISLE) is listed on NASDAQ.What sector and industry is ISLE in?
Isleworth Healthcare Acquisition Corporation operates in the Industrials sector, Consumer Electronics/Appliances industry.When did Isleworth Healthcare Acquisition Corporation go public?
Isleworth Healthcare Acquisition Corporation (ISLE) completed its IPO in 2021.What companies are similar to ISLE?
Notable peers in the same industry include GE (GE Aerospace), SONY (Sony Group Corporation), EMR (Emerson Electric Company), OTIS (Otis Worldwide Corporation), SN (SharkNinja Inc.). Compare ISLE side-by-side with any of them on Quantisnow.How can I track ISLE on Quantisnow?
Quantisnow aggregates Isleworth Healthcare Acquisition Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ISLE to receive live email and push alerts on every new disclosure.